

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>van Hylckama Vlieg Johan</u> _____ (Last) (First) (Middle) <u>C/O KALEIDO BIOSCIENCES, INC</u> _____ (Street) <u>65</u> <u>HAYDEN MA 02421</u> <u>AVENUE</u> _____ (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>05/05/2021</u>	3. Issuer Name and Ticker or Trading Symbol <u>Kaleido Biosciences, Inc. [KLDO]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ <input checked="" type="checkbox"/> Officer (give title below) _____ Other (specify below) _____ <u>Chief Scientific Officer</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) _____ 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
Stock Option (Right to Buy)	(1)	07/30/2029	Common Stock	125,000	7.67	D
Stock Option (Right to Buy)	(2)	11/14/2029	Common Stock	55,000	6.56	D
Stock Option (Right to Buy)	(3)	04/14/2030	Common Stock	40,000	6	D
Stock Option (Right to Buy)	(4)	10/14/2030	Common Stock	40,000	8.69	D
Stock Option (Right to Buy)	(5)	02/28/2031	Common Stock	40,000	9.81	D
Restricted Stock Units ⁽⁶⁾	(7)	02/28/2022	Common Stock	6,707	0.00	D

Explanation of Responses:

- 25% of this option vested on July 1, 2020 with the remainder vesting in 12 equal quarterly installments thereafter.
- 25% of this option vested on November 15, 2020 with the remainder vesting in 12 equal quarterly installments thereafter.
- 25% of this option vested on April 15, 2021 with the remainder vesting in 12 equal quarterly installments thereafter.
- 25% of this option will vest on October 15, 2021 with the remainder vesting in 12 equal quarterly installments thereafter.
- 25% of this option will vest on March 1, 2022 with the remainder vesting in 12 equal quarterly installments thereafter.
- Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.
- The restricted stock units will vest 100% on February 28, 2022.

Remarks:

/s/ Johan van Hylckama Vlieg 05/13/2021
 ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.